Gene · 1022
Papers3,996
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,996
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. | J Med Chem | 2024 | 38586950 | PubTator, text mining | PubMed |
| A narrative review on therapeutic potential of naringenin in colorectal cancer: Focusing on molecular and biochemical processes. | Cell Biochem Funct | 2024 | 38583080 | PubTator, text mining | PubMed |
| AI is a viable alternative to high throughput screening: a 318-target study. | Sci Rep | 2024 | 38565852 | PubTator, text mining | PubMed |
| High-resolution cryo-EM of a small protein complex: The structure of the human CDK-activating kinase. | Structure | 2024 | 38565138 | PubTator, text mining | PubMed |
| Super-enhancer-driven LIF promotes the mesenchymal transition in glioblastoma by activating ITGB2 signaling feedback in microglia. | Neuro Oncol | 2024 | 38554116 | PubTator, text mining | PubMed |
| THZ2 Ameliorates Mouse Colitis and Colitis-Associated Colorectal Cancer. | Biomedicines | 2024 | 38540292 | PubTator, text mining | PubMed |
| Cryo-electron microscopy-based drug design. | Front Mol Biosci | 2024 | 38501110 | PubTator, text mining | PubMed |
| High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. | Nat Commun | 2024 | 38480681 | PubTator, text mining | PubMed |
| A systematic review on understanding the mechanistic pathways and clinical aspects of natural CDK inhibitors on cancer progression.: Unlocking cellular and biochemical mechanisms. | Chem Biol Interact | 2024 | 38467339 | PubTator, text mining | PubMed |
| Structural basis of Cdk7 activation by dual T-loop phosphorylation. | bioRxiv | 2024 | 38405971 | PubTator, text mining | PubMed |
| An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity. | Pharmaceutics | 2024 | 38399219 | PubTator, text mining | PubMed |
| Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer. | Clin Cancer Res | 2024 | 38381406 | PubTator, text mining | PubMed |
| Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. | Br J Cancer | 2024 | 38355841 | PubTator, text mining | PubMed |
| Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer. | Br J Cancer | 2024 | 38355840 | PubTator, text mining | PubMed |
| Small molecule inhibitors of transcriptional cyclin-dependent kinases impose HIV-1 latency, presenting "block and lock" treatment strategies. | Antimicrob Agents Chemother | 2024 | 38319085 | PubTator, text mining | PubMed |
| Ssu72: a versatile protein with functions in transcription and beyond. | Front Mol Biosci | 2024 | 38304578 | PubTator, text mining | PubMed |
| Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC. | Heliyon | 2024 | 38293462 | PubTator, text mining | PubMed |
| Mechanisms of cancer cell death induction by triptolide: A comprehensive overview. | Heliyon | 2024 | 38293343 | PubTator, text mining | PubMed |
| Single metachronous bone metastasis following rectal adenocarcinoma: A case report. | Med Int (Lond) | 2024 | 38283131 | PubTator, text mining | PubMed |
| Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets. | Int J Mol Sci | 2024 | 38279263 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1022/papers?page=11